Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Personalis, Inc. (PSNL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.9600+0.4600 (+10.22%)
At close: 04:00PM EDT
4.9600 0.00 (0.00%)
After hours: 07:18PM EDT
Advertisement

Personalis, Inc.

1330 O’Brien Drive
Menlo Park, CA 94025
United States
650 752 1300
https://www.personalis.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees325

Key Executives

NameTitlePayExercisedYear Born
Mr. John Stephen WestCo-Founder, CEO, Pres & Director1.19MN/A1957
Mr. Aaron L. TachibanaSr. VP & CFO660.02kN/A1961
Dr. Richard Chen M.D., M.S., MSSr. VP of R&D and Chief Medical Officer697.12kN/A1971
Prof. Russ B. Altman M.D., Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/AN/A
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/A1972
Dr. Atul ButteCo-Founder and Member of Clinical & Scientific Advisory BoardN/AN/AN/A
Dr. Michael Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/AN/A
Ms. Carol J. TillisVP of Fin. & Admin.N/AN/AN/A
Mr. Stephen M. Moore J.D.VP, Gen. Counsel & Corp. Sec.N/AN/A1972
Mr. Michael J. FitzpatrickVP of Worldwide SalesN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Corporate Governance

Personalis, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement